atorvastatin has been researched along with Multiple Sclerosis in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (70.59) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Li, J; Lin, J; Peng, X; Su, Z; Weng, Y; Yang, D; Zhang, X | 1 |
| Abtahi Froushani, SM; Delirezh, N; Hobbenaghi, R; Mosayebi, G | 1 |
| Faraji, F; Fazeli, M; Ghasami, K; Ghazavi, A; Mosayebi, G | 1 |
| Engelhardt, B; Findling, O; Grandgirard, D; Greeve, I; Kamm, CP; Leib, SL; Mattle, HP; Minten, C; Sellner, J | 1 |
| Jewells, V; Markovic-Plese, S; Speer, D | 1 |
| Luo, H; Luo, M; Wang, J; Xiao, Y; Zhang, X | 1 |
| Luo, H; Luo, M; Wang, J; Xiao, Y | 1 |
| Wekerle, H | 1 |
| Bravo, M; Hur, EM; Mitchell, DJ; Patarroyo, JC; Radosevich, JL; Ruiz, PJ; Sobel, RA; Steinman, L; Stüve, O; Youssef, S; Zamvil, SS | 1 |
| Koh, CS | 1 |
| Hemmer, B; Nessler, S; Prod'homme, T; Sobel, RA; Steinman, L; Stüve, O; von Büdingen, HC; Weber, MS; Youssef, S; Zamvil, SS | 1 |
| Bradbury, J | 1 |
| Morais, MG; Pedrosa, R; Sena, A | 1 |
| Antipova, V; Bansemer, S; Böttcher, T; Dazert, E; Gierl, L; Gimsa, U; Glass, A; Hoffrogge, R; Ibrahim, SM; Karopka, T; Koczan, D; Kundt, G; Lemcke, S; Mazón-Peláez, I; Mix, E; Müller, J; Pahnke, J; Rolfs, A; Scheel, T; Strauss, U; Warzok, R; Wree, A; Zschiesche, M | 1 |
| Hartung, HP; Neuhaus, O | 1 |
| Antel, J; Arnold, DL; Bar-Or, A; Bodner, CA; Campagnolo, D; Garren, H; Gianettoni, J; Jalili, F; Kachuck, N; Lapierre, Y; Niino, M; Oger, J; Price, M; Rhodes, S; Robinson, WH; Shi, FD; Steinman, L; Utz, PJ; Valone, F; Vollmer, T; Weiner, L | 1 |
| Ballerini, C; Bellucci, A; Biagioli, T; Biamonte, F; Casamenti, F; Grossi, C; Luccarini, I; Massacesi, L; Rosi, MC | 1 |
4 review(s) available for atorvastatin and Multiple Sclerosis
| Article | Year |
|---|---|
Statins for multiple sclerosis.
Topics: Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Multiple Sclerosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention | 2010 |
Statins for multiple sclerosis.
Topics: Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Multiple Sclerosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin | 2011 |
[Effects of atorvastatin in multiple sclerosis].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Encephalomyelitis, Autoimmune, Experimental; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multiple Sclerosis; Pyrroles | 2003 |
Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.
Topics: Atorvastatin; Drug Evaluation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multiple Sclerosis; Pyrroles; Simvastatin | 2007 |
3 trial(s) available for atorvastatin and Multiple Sclerosis
| Article | Year |
|---|---|
Interferon β-1a and Atorvastatin in the Treatment of Multiple Sclerosis.
Topics: Adult; Antioxidants; Atorvastatin; Case-Control Studies; Cytokines; Drug Therapy, Combination; Female; Humans; Interferon beta-1a; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocytes; Male; Middle Aged; Multiple Sclerosis; Nitric Oxide; Treatment Outcome | 2016 |
Beneficial effect of statins in multiple sclerosis: is it dose-dependent?
Topics: Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lovastatin; Multiple Sclerosis; Pyrroles; Simvastatin; Treatment Outcome | 2007 |
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Topics: Adult; Atorvastatin; Disability Evaluation; Double-Blind Method; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immune Tolerance; Immunization; Injections, Intramuscular; Lymphocyte Count; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Myelin Basic Protein; Oligonucleotide Array Sequence Analysis; Plasmids; Pyrroles; Recurrence; T-Lymphocytes; Vaccines, DNA | 2007 |
10 other study(ies) available for atorvastatin and Multiple Sclerosis
| Article | Year |
|---|---|
Beneficial effect of atorvastatin-modified dendritic cells pulsed with myelin oligodendrocyte glycoprotein autoantigen on experimental autoimmune encephalomyelitis.
Topics: Animals; Atorvastatin; Autoantigens; Cell Movement; Cytokines; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Female; Immunologic Factors; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Spinal Cord; Spleen; T-Lymphocytes, Regulatory | 2018 |
Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis.
Topics: Animals; Atorvastatin; Brain; Cytokines; Disease Models, Animal; Drug Synergism; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Heptanoic Acids; Mice; Multiple Sclerosis; Pyrroles; T-Lymphocytes, Regulatory; Tretinoin; Weight Loss | 2014 |
Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis.
Topics: Adolescent; Adult; Atorvastatin; Cytokines; Data Interpretation, Statistical; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon Type I; Interleukin-5; Male; Middle Aged; Multiple Sclerosis; Pyrroles; Recombinant Proteins; Th1 Cells; Th2 Cells | 2008 |
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Central Nervous System; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Heptanoic Acids; Humans; Iatrogenic Disease; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Pyrroles; Risk Assessment | 2009 |
Tackling multiple sclerosis.
Topics: Animals; Antigen Presentation; Atorvastatin; Central Nervous System Diseases; Encephalomyelitis, Autoimmune, Experimental; Heptanoic Acids; Histocompatibility Antigens Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Multiple Sclerosis; Pyrroles; T-Lymphocytes | 2002 |
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Topics: Adoptive Transfer; Amino Acid Sequence; Animals; Antigen-Presenting Cells; Atorvastatin; Cell Division; Central Nervous System Diseases; Cytokines; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Microglia; Molecular Sequence Data; Multiple Sclerosis; Nuclear Proteins; Paralysis; Phosphorylation; Pyrroles; RNA, Messenger; STAT4 Transcription Factor; STAT6 Transcription Factor; Th2 Cells; Trans-Activators | 2002 |
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.
Topics: Animals; Atorvastatin; Cells, Cultured; Cytokines; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Female; Glatiramer Acetate; Heptanoic Acids; Immunologic Factors; Mice; Mice, Inbred Strains; Monocytes; Multiple Sclerosis; Peptides; Pyrroles; T-Lymphocytes, Regulatory; Th1 Cells | 2006 |
Atorvastatin and glatiramer acetate: new hope in MS?
Topics: Adjuvants, Immunologic; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Disease Models, Animal; Drug Therapy, Combination; Glatiramer Acetate; Heptanoic Acids; Humans; Immunotherapy; Inflammation; Multiple Sclerosis; Peptides; Pyrroles | 2006 |
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE.
Topics: Animals; Atorvastatin; Encephalomyelitis, Autoimmune, Experimental; Flow Cytometry; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Lymph Nodes; Male; Mice; Multiple Sclerosis; Myelin Proteolipid Protein; Oligonucleotide Array Sequence Analysis; Peptide Fragments; Pyrroles; Spinal Cord | 2006 |
Combined treatment with atorvastatin and minocycline suppresses severity of EAE.
Topics: Animals; Anti-Bacterial Agents; Atorvastatin; Body Weight; Cell Proliferation; Cytokines; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunosorbent Assay; Female; Glial Fibrillary Acidic Protein; Glycoproteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Minocycline; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Neurologic Examination; Peptide Fragments; Pyrroles; Stereotaxic Techniques; T-Lymphocytes; Time Factors | 2008 |